Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
Frontiers in endocrinology · 2026 · Kierzkowski F, Skrzypek W, Bryl W et
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 15 20:00 ETSource: Frontiers in endocrinology
From the source
Read at pubmed.ncbi.nlm.nih.govBeyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
Frontiers in endocrinology · 2026 · Kierzkowski F, Skrzypek W, Bryl W et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42964480/
